Keith Gottesdiener

President and Chief Executive Office at Prime Medicine

President and Chief Executive Officer
2011 - 2020
Rhythm develops drugs for rare genetic forms of obesity, as well as other metabolic diseases including diabetes and functional GI disorders. Since 2011, we have: Grown from 4 to >100 full-time employees or supporting staff Grown in valuation from ~$40M to > $1B Successfully completed 7 private/3 public financing rounds; raised total capital approaching $700M M&A transaction with Allergan for our initial lead, relamorelin with total value of ~ $450M Our current lead, setmelanotide is set to be filed with FDA and EMA by first half of 2020 Currently studying >10 indications, with 4 identified as Breakthrough Therapy Designation

Head Late Development (2009-11)-Clinical Head ID/Vaccines (2006-08)-Head Early Development (2001-06)
1995 - 2011
During my time at Merck, I led, and was responsible for three areas: (1) Early Development, across therapeutic areas, taking compounds from the laboratory into man through Proof of Concept; (2) Merck's vaccine and infectious disease development activities, including the filings and approvals of Gardasil, Zostavax, Isentress and Boceprevir; and (3) Late Development across all therapeutic areas, from Phase 2 thru patent expiry. Major program responsibilities and/or leading role to approval for >12 major novel drugs Led the early development activities for >200 pre-IND to Phase 2 programs across therapeutic areas.

Assistant (1987-1994) and Associate (1994-2004) Professor
1987 - 2004
From 1987 to 2004, I was an assistant profess or medicine at Columbia, running a basic research laboratory in molecular biology and immunology of parasites, with NIH RO1 funding and renewals. I also was a consultant in infectious diseases at Presbyterian Hospital, and did extensive teaching and lecturing in the Medical School. I continued as part-time faculty with teaching and consulting roles after I left the full-time faculty in 1995.

Internship, Residency, Postdoctoral Training and Fellowships
1982 - 1990
Internship and Residency at Brigham and Women's Hospital in Internal Medicine (1982-85) Postdoctoral fellow in research and infectious Diseases at Harvard Longwood Program and DFCI (1985-88) Second Postdoctoral fellowship in genetics at Columbia Medical School (1987-90)